Neglected Tropical Diseases Diagnosis Market Size, Share & Trends Analysis Report By Disease (Dengue, Chikungunya), By Diagnostic Method (Conventional, Molecular/Modern), By Service Type, By End-use- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global neglected tropical diseases (NTD) diagnosis market size was exhibited at USD 7.29 billion in 2022 and is projected to hit around USD 11.33 billion by 2032, growing at a CAGR of 4.5% during the forecast period 2023 to 2032.

Key Pointers:

• Asia Pacific held a 35.36% share of the neglected tropical diseases diagnosis market in 2022. 
• Latin America is expected to show the fastest CAGR of 5.4% during the projected period 
• Based on disease, soil-transmitted helminthiases dominated the market in 2022
• The dracunculiasis segment is estimated to exhibit the fastest CAGR of 5.6% during the forecast period.
• The molecular/modern diagnostic segment dominated the market in 2022 with a revenue share of around 50.07%,
• point-of-care products is expected to boost the market expansion at a CAGR of 5.1% by 2032.
• Centralized service was the largest segment in terms of market share in 2022,
• The clinical laboratory segment held the largest market share in terms of revenue in 2022,
• The hospitals/clinics segment held the second-largest market share in 2022

Neglected Tropical Diseases Diagnosis Market Report Scope

Growing awareness of NTDs and an increasing number of initiatives undertaken by the government are anticipated to fuel the market growth. For instance, the inclusion of NTDs in the Sustainable Development Goals (SDG), a United Nations Development Program, as a global target is anticipated to fuel market growth. Furthermore, various initiatives being undertaken by WHO, such as road map 2030 for the elimination of NTDs, are expected to drive market growth during the forecast period.

In the wake of the COVID-19 pandemic, the neglected tropical disease (NTD) diagnosis witnessed a significant decline. WHO launched the Global Program to Eliminate Lymphatic Filariasis (GPELF) in 2000, which aims to stop the spread of the infection and relieve the pain of those who have already been afflicted. However, according to the pulse survey conducted by WHO, as of early 2021, the neglected tropical disease program has faced disruptions in 45% of countries. Moreover, the high risk of transmission of SARS-CoV-2 infection has affected the public health approaches for NTDs. In countries with low health budgets, funds being shifted to tackle other diseases, and a shortage of funding from international partners and the foreign government has significantly impacted the growth of the market.

The NTD program has expanded its support to 31 countries in Asia, Latin America, and Africa. Besides, it has provided more than 2.9 billion treatments and leveraged more than USD 23.3 billion in donated medicines. Government organizations such as CDC and WHO collaborate with counties to improve existing public health services for NTDs. Moreover, in January 2022, the WHO introduced its roadmap for NTDs for the period 2023 to 2032. It is aimed to increase the prevention and control of neglected tropical diseases worldwide. Such initiatives undertaken by the government bodies are anticipated to drive the market growth during the forecast period.

Globally, several organizations initiated multiple programs, which contribute to rising in the awareness of NTDs, including the Global NTD Program by the Centers for Disease Control and Prevention, Global NTD Programs by the World Health Organization, NTD Program by the United States Agency for International Development, the United States Global Health Initiative. The primary focus of all these programs is on controlling or eliminating NTDs. Similarly, the London Declaration was initiated to sustain, expand, and extend different programs to support & control guinea worm disease, leprosy, lymphatic filariasis, sleeping sickness, trachoma, schistosomiasis, and Chagas disease by 2020.

The increasing burden of NTDs is considered to be a major factor fueling the growth of the overall market during the forecast period. According to WHO estimates, more than 1.7 billion individuals, about one-fifth of the world’s population, mostly in lower-income and developing countries-required interventions for at least one NTD every year. Around 40% of the African region was affected by NTDs. These diseases are more prevalent among the poor population living in tropical environments and difficult-to-access areas. Countries such as Brazil, Yemen, India, Bangladesh, China, and some countries in Central & East Africa contribute the majority of NTD cases globally.

Some of the prominent players in the Neglected Tropical Diseases Diagnosis Market include:

• F. Hoffmann-La Roche Ltd
• Abbott
• Thermo Fisher Scientific Inc.
• ZeptoMetrix
• InBios International, Inc.
• Genome Diagnostics Pvt. Ltd.
• Omega Diagnostics Group PLC
• Coris BioConcept
• DiaSys Diagnostic Systems GmbH
• Oscar Medicare Pvt Ltd.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Neglected Tropical Diseases Diagnosis market.

By Disease 

• Dengue
• Chikungunya
• Rabies
• Leprosy
• Buruli Ulcer
• Yaws
• Lymphatic Filariasis
• Taeniasis/Cysticercosis
• Foodborne Trematodiases
• Echinococcosis
• Chagas Disease (American Trypanosomiasis)
• Dracunculiasis
• African Trypanosomiasis
• Soil-transmitted Helminth Infections
• Onchocerciasis
• Schistosomiasis
• Scabies and Other Ectoparasites
• Snakebite Envenoming
• Leishmaniasis

By Diagnostic Method 

• Conventional Method
• Molecular/Modern Method

By Service Type 

• Centralized Service
• POC Service

By End-Use 

• Clinical Labs
• Hospitals /Clinics
• Home Healthcare

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)